Clinical Overview
Amitriptyline is a tricyclic antidepressant primarily indicated for the management of major depressive disorder, particularly endogenous depression. It demonstrates significant efficacy in alleviating both the depressive symptoms and associated anxiety components common in clinical depression.
Primary Clinical Applications
Amitriptyline is most effective in treating moderate to severe depression, particularly with melancholic/endogenous features. Its sedative properties make it particularly valuable for patients presenting with significant anxiety alongside their depressive symptoms. The medication is not recommended for mild depressive states or situational depressive reactions.
Mechanism and Onset
As a tricyclic antidepressant, amitriptyline works by inhibiting the reuptake of norepinephrine and serotonin. While sedative effects typically appear rapidly, the full antidepressant response may take 3-4 days to 30 days to develop adequately, requiring patient counseling regarding delayed therapeutic onset.
Key Clinical Monitoring
Due to amitriptyline’s anticholinergic properties and cardiovascular effects, careful monitoring is essential, particularly in patients with cardiac disease, seizure history, or narrow-angle glaucoma. The drug carries significant drug interaction potential, especially with MAOIs, and requires careful consideration in patients receiving concurrent medications.
Prescribing Information
Dosing & Administration
Adults – Outpatients:
- Initial: 25 mg three times daily or 75 mg at bedtime
- Maintenance: 50-100 mg daily (may increase to 150 mg daily if needed)
- Maximum: 300 mg daily for severely ill hospitalized patients
Elderly Patients:
- Initial: 10-25 mg at bedtime
- Maintenance: 25-50 mg daily
Indications
- Major depressive disorder in adults
- Off-label: Chronic pain, migraine prevention, insomnia, PTSD
Contraindications
- Recent myocardial infarction
- Concurrent MAOI use (within 14 days)
- Known hypersensitivity to tricyclic antidepressants
- Acute recovery phase following myocardial infarction
Warnings & Precautions
- Boxed Warning: Increased suicidal risk in patients under 25 years
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Anticholinergic effects: Use caution in elderly patients
- Seizure risk: Lower seizure threshold
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CNS depressants: Enhanced sedation
- Anticholinergic drugs: Additive anticholinergic effects
- CYP2D6 inhibitors: Increased amitriptyline levels
Adverse Reactions
Common (>10%):
- Drowsiness, dizziness, dry mouth, constipation, blurred vision
Serious:
- Cardiac arrhythmias, seizures, anticholinergic toxicity
Special Populations
- Pregnancy: Category C – use only if benefits outweigh risks
- Renal Impairment: Dose adjustment may be necessary
- Hepatic Impairment: Use with caution, consider dose reduction
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
